Modafinil

Overview

Modafinil is a wakefulness-promoting agent (a 'eugeroic') first developed in France in the 1970s and approved by the FDA in 1998 for excessive daytime sleepiness due to narcolepsy. It was subsequently approved for shift-work sleep disorder and obstructive sleep apnea. Unlike classical stimulants (amphetamines, methylphenidate), modafinil produces minimal peripheral sympathomimetic effects at therapeutic doses, does not typically cause the euphoria and post-dose crash of amphetamines, and has substantially lower abuse potential — though it is a Schedule IV controlled substance in the United States. Modafinil has become widely studied as a cognitive enhancer in healthy, non-sleep-deprived individuals, where systematic reviews confirm consistent benefits on attention, executive function, and complex problem-solving. It is available by prescription only in most jurisdictions.

Mechanism of Action

Modafinil's mechanism is pharmacologically atypical and not fully characterized. Its best-established action is weak-to-moderate inhibition of the dopamine transporter (DAT), which raises extracellular dopamine — particularly in the striatum and nucleus accumbens — and is considered necessary for its wakefulness effects (D1/D2 receptor-dependent in knockout studies). Secondary mechanisms include inhibition of the norepinephrine transporter (NET), activation of orexin/hypocretin neurons in the lateral hypothalamus, elevated histaminergic activity in the tuberomammillary nucleus, and modulation of glutamate and GABA balance in cortical circuits. This broad, distributed action on arousal and executive-control systems — rather than a single high-affinity receptor — likely explains modafinil's relatively clean side-effect profile compared to classical stimulants.